KENGREXAL

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug KENGREXAL contains one active pharmaceutical ingredient (API):

1	Cangrelor UNII 2144G00Y7W - CANGRELOR TETRASODIUM
	Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation in vitro and ex vivo. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signalling and platelet activation.
	Read more about Cangrelor

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KENGREXAL Powder for concentrate solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AC25		B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC25

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1683110
ES	Centro de información online de medicamentos de la AEMPS	115994001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	125981
FR	Base de données publique des médicaments	63207425
GB	Medicines & Healthcare Products Regulatory Agency	348664
IT	Agenzia del Farmaco	044016018
LT	Valstybinė vaistų kontrolės tarnyba	1076044
NL	Z-Index G-Standaard, PRK	127590
PL	Rejestru Produktów Leczniczych	100342944
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W63994001
TR	İlaç ve Tıbbi Cihaz Kurumu	8699822780447